Physician profile
David Simonds
NPI 1831148295
$965.31
in general payments reported to CMS, 2019-2025
24 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $90.38 · 2022: $129 · 2024: $39.72 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $145.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $118.26 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $62.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $57.88 | 2019-2020 | |
| Mylan Specialty L.P. | $53.07 | 2019-2020 | |
| Genentech USA, INC. | $48.62 | 2019-2020 | |
| Boston Scientific Corporation | $39.72 | 2024 | Ekosonic |
| Phadia US INC. | $34.38 | 2019 | |
| Vifor Pharma, INC. | $33.59 | 2019 | |
| Pfizer INC. | $32.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.09 | 2019 | |
| Circassia INC. | $31.48 | 2019 | |
| Allergan, INC. | $31.31 | 2019 | |
| Glaxosmithkline, LLC. | $30.32 | 2019 | |
| Resmed Corp | $29.99 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $29.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.89 | 2019 | |
| Philips North America LLC | $20.70 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.70 | 2019 | |
| Merck Sharp & Dohme LLC | $16.65 | 2019 | |
| Fresenius USA Marketing, INC. | $15.68 | 2019 | |
| La Jolla Pharmaceutical Company | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.